SandipPravinPatelMD

Hematologic Oncology, Thoracic Cancer

Associate Professor, UCSD Co-Leader, Experimental Therapeutics Deputy Director, San Diego Center for Precision Immunotherapy Director, Clinical Trials Office

Join to view full profile

Dr. Patel is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Patel's full profile

Already have an account?

Office
3855 Health Sciences Drive
La Jolla, CA 92093
Phone(858) 822-6580
Fax(858) 822-6186
Is this information wrong?

Summary

Early phase clinical trials of cancer immunotherapy, solid tumor cellular therapy, thoracic immunooncology, spatial immune profiling, irAEs

Education & Training

Duke University HospitalFellowship, Hematology/Oncology, 2011
UCLA Medical CenterResidency, Internal Medicine, 2008 - 2011
Baylor College of MedicineClass of 2008
Duke UniversityBA, Political Science, Magna Cum Laude, 2000 - 2004

Certifications & Licensure

NC State Medical License 2011 - 2014
CA State Medical License 2009 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Commendation for Excellence in Medical Student Teaching 2008 - 2009, 2009
“Most Awards” Award 2008 - 2009, 2009
Dean’s List 2000 - 2001, 2000 - 2002, 2002
Dean’s List w/t Distinction 2002
Killson Educational Foundation Scholarship
Phi Beta Kappa National Academic Honor Society
Pi Sigma Alpha National Political Science Honor Society
Goldwater Scholarship semifinalist for Duke University
National Merit Scholarship Winner, National Advanced Placement Scholar with Distinction High School
National Qualifier for Quiz Bowl, Fourth place at national TEAMS engineering contest, State Qualifier for Debate
Join now to see all

Clinical Trials

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioblastoma Start of enrollment: 2015 Oct 01Antonia S.,Hong D.,Patel S.,Reardon D.,Saleh M.,Vlahovic G.
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer Start of enrollment: 2012 Jun 01
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine Arthur P. DeCillis, MD
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread Bristol-Myers Squibb
An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer Bristol-Myers Squibb
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed Bristol-Myers Squibb
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC Sandip Patel, MD
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Sandip Patel
Join now to see all

Publications & Presentations

PubMed

Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response.
Patel, S. P., Othus, M., Chae, Y. K., Kurzrock, R.> ;Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 May 18
HASH(0x2709df8)
Kato, S.,Okamura, R.,Mareboina, M.,Lee, S.,Goodman, A.,Patel, S. P.,Fanta, P. T.,Schwab, R. B.,Vu, P.,Raymond, V. M.,Lanman, R. B.,Sicklick, J. K.,Lippman, S. M.,Kurzr...> ;JCO Precis Oncol. 2019 May 07
HASH(0x2373e48)
Bordin-Wosk, T.,Patel, S. P.,Horman, S. F.> ;J Gen Intern Med. 2019 May 08
A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.
Guram, K.,Kim, S. S.,Wu, V.,Sanders, P. D.,Patel, S.,Schoenberger, S. P.,Cohen, EEW.,Chen, S. Y.,Sharabi, A. B.> ;Front Immunol. 2019 Apr 03
Next generation predictive biomarkers for immune checkpoint inhibition.
Khagi Y, Kurzrock R, Patel SP> ;Cancer metastasis reviews.
Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes.
Tray, N., Tray, N., Tray, N., Tray, N., Tray, N., Tray, N., Tray, N., Tray, N., Tray, N., Tray, N., Tray, N., Tray, N., Tray, N., Tray, N., Tray, N., Tray, N., Tray, N...> ;Breast (Edinburgh, Scotland). 2019 Jan 5
Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tum...
Tran B, Carvajal RD, Marabelle A, Patel SP, LoRusso PM, Rasmussen E, Juan G, Upreti VV, Beers C, Ngarmchamnanrith G, Schöffski P> ;Journal for immunotherapy of cancer. 2018-09-25
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.
Ettinger, D. S.,Aisner, D. L.,Wood, D. E.,Akerley, W.,Bauman, J.,Chang, J. Y.,Chirieac, L. R.,D'Amico, T. A.,Dilling, T. J.,Dobelbower, M.,Govindan, R.,Gubens, M. A.,H...> ;J Natl Compr Canc Netw. 2018 Jul 15
Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment.
Patel NS, Oury A, Daniels GA, Bazhenova L, Patel SP> ;The oncologist. 2018-05-16
Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support.
Chae, Y. K.,Pan, A. P.,Davis, A. A.,Patel, S. P.,Carneiro, B. A.,Kurzrock, R.,Giles, F. J.> ;Mol. Cancer Ther.. 2017 Dec 06
Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.
Schwaederle, M.,Krishnamurthy, N.,Daniels, G. A.,Piccioni, D. E.,Kesari, S.,Fanta, P. T.,Schwab, R. B.,Patel, S. P.,Parker, B. A.,Kurzrock, R.> ;Cancer. 2017 Dec 07
Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.
Khagi, Y.,Goodman, A. M.,Daniels, G. A.,Patel, S. P.,Sacco, A. G.,Randall, J. M.,Bazhenova, L. A.,Kurzrock, R.> ;Clin. Cancer Res.. 2017 Oct 04
{"__content__"=>"Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring Exon 14 Mutations and Overcomes Mutation-mediated Resistance to T...
Engstrom LD, Aranda R, Lee M, Tovar EA, Essenburg CJ, Madaj Z, Chiang H, Briere D, Hallin J, Lopez-Casas PP, Baños N, Menendez C, Hidalgo M, Tassell V, Chao R, Chudova...> ;Clinical cancer research : an official journal of the American Association for Cancer Research. 2017-08-01
Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Con...
Sharabi, A.,Kim, S. S.,Kato, S.,Sanders, P. D.,Patel, S. P.,Sanghvi, P.,Weihe, E.,Kurzrock, R.> ;Oncologist. 2017 May 28
Best practices for the Management of Local-regional Recurrent Chordoma. A Position Paper by the Chordoma Global Consensus Group.
Stacchiotti, S.,Gronchi, A.,Fossati, P.,Akiyama, T.,Alapetite, C.,Baumann, M.,Blay, J. Y.,Bolle, S.,Boriani, S.,Bruzzi, P.,Capanna, R.,Caraceni, A.,Casadei, R.,Colia, ...> ;Ann. Oncol.. 2017 Feb 12
CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.
Osada, T.,Patel, S. P.,Hammond, S. A.,Osada, K.,Morse, M. A.,Lyerly, H. K.> ;Cancer Immunol. Immunother.. 2015 Mar 07
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.
Patel, S. P.,Kurzrock, R.> ;Mol. Cancer Ther.. 2015 Feb 20
Designing effective vaccines for colorectal cancer.
Patel, S. P.,Osada, T.,Lyerly, H. K.,Morse, M. A.> ;Immunotherapy. 2014 Oct 15
Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models.
Patel, S. P.,Bristol, A.,Saric, O.,Wang, X. P.,Dubeykovskiy, A.,Arlen, P. M.,Morse, M. A.> ;Cancer Immunol. Immunother.. 2013 Jun
Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
Patel, S. P., Garcia-Manero, G., Ferrajoli, A., Faderl, S., Verstovek, S., Kantarjian, H., Estey, E.> ;Leuk Res. 2006 Mar
Join now to see all

Abstracts/Posters

Photocrosslinkable Polymers for Biomedical Applications.
Grinstaff MW, Carnahan PS, Fleming DL, Hatchell NR, Luman MT, Patel SP, 222nd American Chemical Society
Abstract #896 appears in Blood, Volume 106, issue 11.
Travel grant recipient and poster presentation, American Society of Hematology Conference 2005
Empiric treatment as a means of diagnosis in AIDS patients with CNS lesions.
Poster Presentation, Society of General Internal Medicine Conference 2009

Lectures

SWOG 1609 (DART): A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

FDA and Doctors Warn Against Extending COVID-19 Vaccine Dose GapJanuary 06, 2021 12:30
Microbe DNA in Blood Samples Could Reveal Clues About Cancer – StudyMarch 18, 2020 08:17
Cancer Clues Detected in the Blood’s Microbial DNAMarch 17, 2020 05:44
Join now to see all